Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $6.72M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: 13.24%
• EPS Growth: 98.80%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.19
• Shares Outstanding: 4,905,945
• 10 Day Avg. Volume: 3,175,467
• 30 Day Avg. Volume: 1,091,586
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -0.14
• Enterprise Value/Market Cap: -1.26
• Enterprise Value/Revenue: -0.23
• Enterprise Value/Gross Profit: -0.69
• Enterprise Value/Ebitda: 1.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.50 ▲(7.91% Upside)

Sunshine Biopharma's overall stock score is primarily impacted by its financial performance and valuation. The company faces significant profitability and cash flow challenges, reflected in a low financial performance score. The technical analysis indicates a bearish trend, while the negative P/E ratio and lack of dividend yield result in a poor valuation score. These factors collectively contribute to a low overall stock score.

Positive Factors

Low Leverage

Low leverage provides financial flexibility and reduces risk, allowing the company to potentially invest in growth opportunities without significant debt burden.

Revenue Growth

Consistent revenue growth, albeit modest, indicates a positive trend in market demand and product acceptance, which can support long-term business expansion.

Stable Gross Profit Margin

A stable gross profit margin suggests effective cost management at the production level, which is crucial for maintaining profitability as the company scales.

Negative Factors

Profitability Challenges

Ongoing profitability issues can hinder the company's ability to reinvest in growth and may necessitate strategic changes to improve financial performance.

Cash Flow Challenges

Negative cash flows indicate potential liquidity issues, which could impact the company's ability to fund operations and growth initiatives without external financing.

Negative Return on Equity

A negative return on equity suggests that the company is not generating sufficient profits from shareholders' investments, which could affect investor confidence and capital raising efforts.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology sector, where it specializes in drug discovery and development, particularly in the areas of oncology and related treatments. Sunshine Biopharma's core products include a pipeline of drug candidates that address unmet medical needs, leveraging advanced technologies to enhance therapeutic efficacy and patient outcomes.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company aims to secure funding through partnerships and collaborations with larger pharmaceutical firms, which can provide financial resources and market access for its drug candidates. Additionally, SBFM may generate income through licensing agreements that allow other companies to use its proprietary technologies or drug formulations. The company may also benefit from government grants and research funding aimed at supporting innovative biopharmaceutical research. As the company progresses in clinical trials and moves toward regulatory approvals, potential sales of its products could significantly contribute to its revenue streams.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma is experiencing strong revenue growth but faces significant challenges in achieving profitability. The balance sheet is stable with low leverage, but negative returns on equity highlight ongoing financial struggles. Cash flow issues persist, with negative operating and free cash flows, indicating liquidity concerns. Overall, while growth prospects are promising, the company needs to address profitability and cash flow management to improve its financial health.

Income Statement

Sunshine Biopharma has shown significant revenue growth in recent periods, particularly with a 29.6% increase in TTM. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin is stable but not sufficient to cover operating expenses, leading to consistent net losses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is reasonable, suggesting a stable asset base relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite this, the free cash flow to net income ratio suggests some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.32M	34.87M	24.09M	4.35M	228.43K	71.41K
Gross Profit	12.32M	10.67M	8.34M	1.70M	110.60K	45.56K
EBITDA	-6.20M	-5.15M	-3.82M	-26.45M	-12.10M	-2.60M
Net Income	-5.99M	-5.13M	-4.51M	-26.74M	-12.44M	-2.78M
Balance Sheet
Total Assets	31.49M	30.56M	27.35M	29.55M	2.20M	1.05M
Cash, Cash Equivalents and Short-Term Investments	9.31M	9.69M	16.29M	21.83M	2.05M	997.48K
Total Debt	854.76K	952.48K	657.71K	765.26K	1.90M	1.91M
Total Liabilities	7.29M	7.06M	6.14M	7.92M	1.99M	2.00M
Stockholders Equity	24.20M	23.50M	21.21M	21.63M	211.66K	-954.84K
Cash Flow
Free Cash Flow	-8.33M	-14.85M	-9.56M	-5.55M	-1.83M	-658.49K
Operating Cash Flow	-7.12M	-12.53M	-8.78M	-5.25M	-1.83M	-657.30K
Investing Cash Flow	-1.32M	-2.32M	-656.15K	-14.62M	0.00	-1.19K
Financing Cash Flow	6.08M	9.29M	3.43M	39.47M	2.90M	1.61M

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Neutral. The current price of 1.39 is above the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.48, and below the 200-day MA of 1.52, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 49.54 is Neutral, neither overbought nor oversold. The STOCH value of 84.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNOA	50 Neutral	$6.43M	-1.72	-76.14%	―	25.02%	55.11%
YCBD	50 Neutral	$10.87M	-0.28	-44.42%	―	-1.50%	80.17%
IMCC	45 Neutral	$7.56M	-1.83	-93.87%	―	-0.74%	81.49%
SBFM	44 Neutral	$6.72M	-0.74	-24.34%	―	13.24%	98.80%
SHPH	32 Underperform	$2.89M	-0.08	-9999.00%	―	―	79.31%

Sunshine Biopharma Corporate Events

Sunshine Biopharma Holds Annual Stockholders Meeting

On December 11, 2025, Sunshine Biopharma Inc. held its annual meeting of stockholders where key decisions were made. The company elected five directors, ratified the appointment of M&K CPAS, PLLC as its independent registered public accounting firm for 2025, and approved an amendment to increase the number of shares in its 2023 Equity Incentive Plan to 683,000. These actions are likely to impact the company’s governance and financial strategies moving forward.

The most recent analyst rating on (SBFM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.